Summary:

«Medicare started covering CGMs for patients on intensive insulin in 2017, and by now, many endocrinologists will prescribe CGMs for type 2 patients who take multiple daily injections of insulin or use an insulin pump. The devices seem to help these patients keep their A1Cs in a healthier range — and prevent acute complications, just like with type 1. Recent claims-based research funded by Abbott has shown that six months of the company’s FreeStyle Libre, a “flash” CGM that collects readings with a swipe over the sensor, can reduce emergency visits and hospitalizations for type 2 patients using insulin.»

Article written by  Katie Palmer. Image by Adobe

30|06|2021

Source:

STAT

https://www.statnews.com/2021/06/30/continuous-glucose-monitoring-type-2-diabetes-primary-care/